ENTX.US Entera Bio Ltd

Healthcare Biotechnology USA Stocks
3.11 USD
Close of Nov 14, 2026
0.9100 4.20
Market cap
USD 542M
P/E
-
P/B
2.04x
ROE
-12.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ENTX.US undervalued?

Graham number

The Graham number of Entera Bio Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Entera Bio Ltd fundamental analysis

No fundamental analysis for Entera Bio Ltd yet.

Entera Bio Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Entera Bio Ltd

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the tre…

Full company profile